Trials Sponsors Conditions Drugs Pricing

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Keywords

BPDCNRetrospectiveSTML-401-0521ELZONRISChemotherapy

Outcome Measures

Primary Outcomes (9)

Objective Response Rate
Baseline through Month 18
Composite Complete Response
Baseline through Month 18
Number of Participants Bridged to Stem Cell Transplant
Baseline through Month 18
Duration of Response
Baseline through Month 18
Real-world Progression-free Survival
Baseline through Month 18

Secondary Outcomes (2)

Time to Next Treatment
Baseline through Month 26
Number of Different First-line Treatment Regimens and Sequences Received
Baseline through Month 26

Study Arms (1)

Chemotherapy

Adult participants with BPDCN who have been treated with chemotherapy regimens (at a minimum) as first-line treatment from May 2016.

Drug: Chemotherapy

Interventions

ChemotherapyDrug

Several chemotherapy regimens can be considered (acute myeloid leukemia-like, acute lymphocytic leukemia-like, lymphoma-like). The choice of the regimen, as well as dosing and schedules, are based on the institution's and the health care provider's preferences. No study medication will be provided by the sponsor during this study.

Chemotherapy

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Adult participants with BPDCN who have been treated with chemotherapy regimens (at a minimum) as first-line treatment from May 2016 at sites in Europe.

You may qualify if:

Alive, deceased, or unreachable participants (as permitted by local regulation), aged ≥18 years at the start of first-line treatment for BPDCN, and treated with chemotherapy regimens (at a minimum) as first-line treatment for BPDCN from May 2016

Sponsors & Collaborators

Stemline Therapeutics, Inc.
Industrylead

Study Sites (67)

Aarhus University Hospital

Aarhus, Denmark

RECRUITING

Odense University Hospital

Odense, Denmark

RECRUITING

Centre Hospitalier Universitaire Besancon

Besançon, France

RECRUITING

Hôpital Avicenne

Bobigny, France

RECRUITING

MeSH Terms

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm

Interventions

Drug Therapy

Condition Hierarchy (Ancestors)

Histiocytic Disorders, MalignantNeoplasms by Histologic TypeNeoplasmsLeukemiaLymphomaHematologic NeoplasmsNeoplasms by SiteSkin NeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

Medical Director
Stemline Therapeutics, Inc.
STUDY DIRECTOR

Central Study Contacts

Stemline Trials

CONTACT

1-877-332-796 clinicaltrials@menarinistemline.com

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 20, 2026

First Posted

August 25, 2026

Study Start

October 17, 2025

Actual (reported)

Primary Completion

May 2027

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (9)

Secondary Outcomes (2)

Study Arms (1)

Chemotherapy

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (67)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (9)

Secondary Outcomes (2)

Study Arms (1)

Chemotherapy

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (67)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Locations